Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine

Veterinary Dermatology

Volumn 16, Issue 5, 2005, Pages 338-345

  Callan, Mary Beth ^a   Preziosi, Diane ^a,b   Mauldin, Elizabeth ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Veterinary Specialists of Alaska   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; PREDNISONE;

ANEMIA; ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; DOG; DOG DISEASE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HAMARTOMA; IMMUNE DEFICIENCY; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; VIRUS INFECTION;

ANEMIA; ANIMALS; CARCINOMA, SQUAMOUS CELL; CYCLOSPORINE; DIAGNOSIS, DIFFERENTIAL; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HAMARTOMA; IMMUNOCOMPROMISED HOST; PAPILLOMAVIRUS INFECTIONS; PREDNISONE; SKIN NEOPLASMS;

CANIS FAMILIARIS; PAPILLOMAVIRUS;

EID: 27744573593     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2005.00466.x     Document Type: Article

References (38)

1. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000; 47: 63-83.
2. Mathews KA, Sukhiani HR. Randomized controlled trial of cyclosporine for treatment of perianal fistulas in dogs. Journal of the American Veterinary Medical Association 1997; 211: 1249-53.
3. Olivry T, Steffan J, Fisch RD et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. Journal of the American Veterinary Medical Association 2002; 221: 370-7.
4. Olivry T, Rivierre C, Jackson HA et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisone-controlled trial. Veterinary Dermatology 2002; 13: 77-87.
5. Linek M, Boss C, Haemmerling R et al. Effects of cyclosporine A on clinical and histologic abnormalities in dogs with sebaceous adenitis. Journal of the American Veterinary Medical Association 2005; 226: 59-64.
6. Guaguère E, Steffan J, Olivry T. Cyclosporine A: a new drug in the field of canine dermatology. Veterinary Dermatology 2004; 15: 61-74.
7. Nagata M, Nanko H, Moriyama A et al. Pigmented plaques associated with papillomavirus infection in dogs: Is this epidermodysplasia verruciformis? Veterinary Dermatology 1995; 6: 179-86.
8. Tanabe C, Kano R, Nagata M et al. Molecular characteristics of cutaneous papillomavirus from the canine pigmented epidermal nevus. Journal of Veterinary Medical Science 2000; 62: 1189-92.
9. Nodarse-Cuni H, Iznaga-Marin N, Viera-Alvarez D et al. Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report). Journal of Laryngology and Otology 2004; 118: 681-7.
10. Aaron S, Wong E, Tyrrell D et al. Interferon treatment of multiple pulmonary malignancies associated with papilloma virus. Canadian Respiratory Journal 2004; 11: 443-6.
11. Risse L, Negrier P, Dang PM et al. Treatment of verrucous carcinoma with recombinant alfa-interferon. Dermatology 1995; 190: 142-4.
12. Sikorski M, Zrubek H. Long-term follow-up of patients treated with recombinant human interferon gamma for cervical intraepithelial neoplasia. International Journal of Gynecology and Obstetrics 2003; 82: 179-85.
13. Stokking LB, Ehrhart EJ, Lichtensteiger CA et al. Pigmented epidermal plaques in three dogs. Journal of the American Animal Hospital Association 2004; 40: 411-17.
14. Johnson JA, Gangemi JD. Alpha interferon augments cidofovir's antiviral and antiproliferative activities. Antimicrobial Agents and Chemotherapy 2003; 47: 2022-6.
15. Eedy DJ. Imiquimod: a potential role in dermatology? British Journal of Dermatology 2002; 147: 1-6.
16. Hengge UR, Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. British Journal of Dermatology 2003; 149: 15-19.
17. Miller RL, Gerster JF, Owens ML et al. Imiquimod applied topically: a novel response modifier and new class of drug. International Journal of Immunopharmacology 1999; 21: 1-14.
18. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
19. Rosenkrantz WS, Griffin CE, Barr RJ. Clinical evaluation of cyclosporine in animal models with cutaneous immune-mediated disease and epitheliotropic lymphoma. Journal of the American Animal Hospital Association 1989; 25: 377-84.
20. White JV. Cyclosporine: prototype of a T-cell selective immunosuppressant. Journal of the American Veterinary Medical Association 1986; 189: 566-70.
21. Feldman EC, Alejandro R. Red blood cell and serum biochemical alterations in dogs receiving long-term cyclosporine therapy. Transplantation 1988; 45: 837-40.
22. Seibel W, Yahia NA, McCleary LB et al. Cyclosporine-induced gingival overgrowth in beagle dogs. Journal of Oral Pathology and Medicine 1989; 18: 240-5.
23. O'Hara AJ, Collins T, Howell JMC. Gingival eruption cysts induced by cyclosporine administration to neonatal dogs. Journal of Clinical Periodontology 2002; 29: 507-13.
24. Werner AH. Psoriasiform-lichenoid-like dermatosis in three dogs treated with microemulsified cyclosporine A. Journal of the American Veterinary Medical Association 2003; 223: 1013-16.
25. Seibel W, Sundberg JP, Lesko LJ et al. Cutaneous papillomatous hyperplasia in cyclosporine-A treated beagles. Journal of Investigative Dermatology 1989; 93: 224-30.
26. Le Net J-L, Orth G, Sundberg JP et al. Multiple pigmented cutaneous papules associated with a novel canine papillomavirus in an immunosuppressed dog. Veterinary Pathology 1997; 34: 8-14.
27. Alam M, Ratner D. Cutaneous squamous cell carcinoma. New England Journal of Medicine 2001; 344: 975-83.
28. Bregman CL, Hirth RS, Sundberg JP et al. Cutaneous neoplasms in dogs associated with canine oral papillomavirus vaccine. Veterinary Pathology 1987; 24: 477-87.
29. Miller WH, Affolter V, Scott DW et al. Multiple squamous cell carcinomas in situ resembling Bowen's disease in five cats. Veterinary Dermatology 1992; 3: 177-82.
30. Baer KE, Helton K. Multicentric squamous cell carcinoma in situ resembling Bowen's disease in cats. Veterinary Pathology 1993; 30: 535-43.
31. LeClerc SM, Clark EG, Haines DM. Papillomavirus infection in association with feline cutaneous squamous cell carcinoma in situ. In: Proceedings of the Thirteenth Annual Meeting of the American Association of Veterinary Dermatology and the American College of Veterinary Dermatology. 1997: 125-6.
32. Glover MT, Deeks JJ, Raftery MJ et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant subjects. Lancet 1997; 349: 398.
33. Jensen P, Hansen S, Moller B et al. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transplantation Proceedings 1999; 31: 1120.
34. Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transplantation 2002; 8: 939-44.
35. Tremblay F, Fernandes M, Habbab F et al. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Annals of Surgical Oncology 2002; 9: 785-8.
36. Van de Kerkhof PCM, De Rooij MJM. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporine treatment: response to long-term acitretin maintenance. British Journal of Dermatology 1997; 136: 275-8.
37. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin; nested cohort crossover study. Lancet 2001; 358: 1042-5.
38. Agnew KL, Bunker CB. Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. Journal of the European Academy of Dermatology and Venereology 2003; 17: 113-14.